Metraipolis › archive › dc_6deea80ab88f

Therapeutic efficacy and safety profile of SGLT-2 inhibitor dapagliflozin in heart failure with reduced and preserved ejection fraction: a systematic review… — Europe PMC PMID:41180724

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41180724
DOI
10.1097/ms9.0000000000003744
License (as archived)
solo-consultazione
Archived
2026-11-10T03:09:34.500Z
SHA-256 of the archived text
c2b764cf44668ebe6d5e6e6580908dbcc9be120b2306f7a58acb0cd28c472f5e
Stable URL of this page
https://metraipolis.com/documento/dc_6deea80ab88f

How to cite

Therapeutic efficacy and safety profile of SGLT-2 inhibitor dapagliflozin in heart failure with reduced and preserved ejection fraction: a systematic review… — Europe PMC PMID:41180724 — Europe PMC (en), https://europepmc.org/article/MED/41180724 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6deea80ab88f (Metraipolis archive dc_6deea80ab88f, sha256 c2b764cf44668ebe6d5e6e6580908dbcc9be120b2306f7a58acb0cd28c472f5e)
BibTeX
@misc{dc6deea80ab88f,
  title = {Therapeutic efficacy and safety profile of SGLT-2 inhibitor dapagliflozin in heart failure with reduced and preserved ejection fraction: a systematic review… — Europe PMC PMID:41180724},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41180724},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6deea80ab88f; sha256 c2b764cf44668ebe6d5e6e6580908dbcc9be120b2306f7a58acb0cd28c472f5e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41180724. Agents can read the archived copy with the MCP tool read_document.